Ignite Creation Date:
2025-12-24 @ 3:17 PM
Ignite Modification Date:
2026-01-04 @ 9:21 AM
Study NCT ID:
NCT04055792
Status:
COMPLETED
Last Update Posted:
2023-06-28
First Post:
2019-08-11
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Sintilimab Combined With Anlotinib as Second or Further-line Therapy for ED-SCLC
Sponsor:
Henan Cancer Hospital
Organization:
Organization Data
Organization:
Class:
OTHER_GOV
Study ID:
20200526
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
OTHER_GOV
Responsible Party:
Responsible Party Title:
Responsible Party Type:
PRINCIPAL_INVESTIGATOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None